The U.S. Food and Drug Administration and the FDA have approved the emergency use of the COVID-19 vaccine developed by Pfizer-Bioentech.
Bioentech has announced that it will supply the vaccine to Europe from early next year.
Reporter Kim Jin-ho.
The U.S. Food and Drug Administration, FDA approved Pfizer-Bioentech’s emergency use of the COVID-19 vaccine.
The approval came one day after the advisory committee recommended approval, and foreign media reported that there was external pressure from the White House.
The FDA stressed that it was a scientific evaluation through a video interview.
[스티븐 한 / FDA 국장 : 과학과 데이터가 FDA 결정을 이끌었습니다. 세계적 대유행의 긴급함 때문에 빠른 결정을 한 것이지 외부 압력 때문은 아닙니다.]
The United States is the sixth country to approve Pfizer vaccines, after the United Kingdom and Canada.
As the FDA’s urgent approval decision is accelerated, the initiation date is likely to be extended.
President Trump stressed that it should be within 24 hours.
[도널드 트럼프 / 미국 대통령 : 24시간 안에 백신 접종이 시작될 겁니다. 각 주지사가 백신이 어디로 갈지, 누구를 먼저 맞힐지 결정할 것입니다.]
BioEntech, which applied for emergency use to the European Medicines Agency and EMA, said it would supply it to Europe early next year.
[우구르 사힌 / 바이오엔테크 CEO : 조건부 승인을 올해 말에 받으면 내년 초에 유럽 여러 나라에 백신을 공급할 수 있게 될 것입니다.]
To increase production, Bioentech acquired a vaccine production facility in Marburg, western Germany from Swiss company Novartis in September, and is working to accelerate the scheduled operation in the first half of next year.
This is YTN Kim Jin-ho.
[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]